GRI (38) ONCO (36) CVKD (40) EOCN (47) ⌘ Pro Terminal →

Ernexa Therapeutics Inc. (ERNA) — RQD Stock Rating Cockpit

$2.11 +6.57% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Ernexa Therapeutics Inc. (ERNA) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $3.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ERNA)Realized 20D OHLCV Swing Band: ±12.5%

RSI-14 MOMENTUMNEUTRAL RANGE

32.330 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

3 / 99-Pt Accounting

52-WEEK LASER RANGE2% OF RANGE

L: $2$2.11H: $47

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 6 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 17 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 23 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on ERNA

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (30)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (50)

17/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like ERNA

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ERNA)

✓Walkthrough of ERNA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ERNA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -43.73%⚡ TESTING RESISTANCE

2026-10-30O $2.08H $2.14L $1.95C $2.11VOL 4.5K

RES: $2.79SUP: $1.60SMA50: $3.31SMA200: $7.35

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ERNA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ERNA Butterfly Map → + Track ERNA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ERNA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ERNA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ERNA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ERNA)

Health Care Rank #463 of 1016 ⚔️ GRI vs ERNA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ERNA vs. GRI, ONCO, CVKD, EOCN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Ernexa Therapeutics Inc. (ERNA) ranks #463 by composite RQD confidence (46/100, grade D) and #972 by equity capitalization ($3.4M). Within this direct 5-issuer industry benchmark cohort, ERNA leads on earnings valuation at N/A trailing P/E, while ERNA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. EOCN currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with ERNA at 46/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ERNA ACTIVE Ernexa Therapeutics Inc.	D	46/100	—	—	-35.0%	+6.57%	$3.4M	Benchmark Subject
GRI GRI Bio Inc.	D-	38/100	—	—	-35.0%	-3.38%	$3.4M	/gri-vs-erna →
ONCO Onconetix Inc.	D-	36/100	—	77.6%	-35.0%	-1.99%	$3.5M	/onco-vs-erna →
CVKD Cadrenal Therapeutics Inc.	D-	40/100	—	—	-35.0%	-0.47%	$3.4M	/cvkd-vs-erna →
EOCN Eocene Ltd.	D	47/100	—	—	-35.0%	+0.62%	$3.4M	/eocn-vs-erna →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000748592

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Ernexa Therapeutics Inc. (ERNA) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $582.0K , and -100.0% cumulative change since FY2023) , GAAP net income of -$14.1M, operating cash flow of -$7.0M, and free cash flow of -$7.1M (+56.5% YoY). On the balance sheet, ERNA closed FY2025 with $5.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$14.1M	-$7.0M	-$7.1M	$5.8M	—
FY2024 (FY)	2024-12-31	$582.0K	-$44.5M	-$15.8M	-$16.2M	$5.3M	—
FY2023 (FY)	2023-12-31	$68.0K	-$21.7M	-$20.4M	-$20.4M	—	—

3. ERNA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ERNA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Ernexa Therapeutics Inc. (NASDAQ: ERNA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $2.11 (+6.57% 1D, market cap $3.4M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ERNA ranks #463 in composite RQD confidence.

How does ERNA compare to GRI and ONCO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ERNA carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GRI (GRI Bio Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $3.4M) and ONCO (Onconetix Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $3.5M). Among the 5-stock peer group, ERNA leads on earnings multiple (N/A) while ERNA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ERNA?

Per ERNA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000748592), Ernexa Therapeutics Inc. generated $0 in revenue (-100.0% YoY), -$14.1M in net income, and -$7.1M in free cash flow against $5.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ERNA trading relative to its 50-day, 200-day, and 52-week technical levels?

ERNA last traded at $2.11 (+6.57% on volume of 7,284 shares), positioning the stock -36.25% below its 50-day simple moving average ($3.31) and -71.29% below its 200-day simple moving average ($7.35). Across its 52-week range of $1.84 to $47.25, ERNA sits at the 0.6% percentile with a 14-day RSI of 32.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.85 to $2.37).

ERNA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell ERNA stock right now?

Ernexa Therapeutics Inc. (ERNA) currently earns a Roarable Rating of D (Sell — SELL) with 46/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is ERNA's 12-month price target and RQD AI Jury consensus?

ERNA's 12-month base price target is $2 (range $1.56 to $49.61), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: ERNA RQD Cockpit ERNA 12M Forecast ERNA Earnings & Move ERNA Dividends & DRIP ERNA Insiders & 13F ERNA Whale Options ERNA Profit Sankey ERNA News & Why